Product Description

Anti-HRSV Fusion Protein Reference Antibody (Motavizumab, RUO)

Sizes: 100ug, 1mg

Catalogue Numbers: VK421036-100, VK421036-1000

Lead times: 1-2 weeks, if manufacturer has product in stock

Manufacturer/Ship Location: China

Description: Motavizumab (MEDI-524, NUMAX, NISTmAb) is a second generation monoclonal antibody (mAb) derived from palivizumab (Synagis) using affinity maturation techniques. Motavizumab is currently undergoing US Food and Drug Administration review as a treatment for respiratory syncytial virus (RSV) prophylaxis. It has been evaluated in large-scale clinical studies, and has demonstrated efficacy in reducing the disease burden of RSV in high-risk infant populations. Motavizumab (MEDI-524, NUMAX, NISTmAb) has higher affinity and a longer half-life, was effective in reducing RSV hospitalization in high-risk full-term infants in the US, but was not licensed due to safety concerns (allergic reactions).

Reactivity: HRSV-A

Host: Humanized

Applications: ELISA, Bioactivity: FACS, Functional assay

Alternate Names: MEDI-524, NUMAX, NISTmAb, CR9503, 677010-34-3

Clonality: Monoclonal

Isotype: IgG1, kappa

Target: F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1

Purification: Protein A/G purified from cell culture supernatant.

Purity: >95% purity as determined by SDS-PAGE.

Expression System: Mammalian Cells

Storage and Stability: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

Storage Buffer: 0.01M PBS, pH 7.4.

Form: Liquid

Accession: P03420

Endotoxin Level: Please contact the lab for this information.

Research Use Only